PREFER

CompletedPhase 4

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications

A Randomized, Open-label, Cross-over Study to Evaluate Patient Preferences for Eucreas® Versus Victoza® as add-on to Metformin in Type 2 Diabetes Mellitus Patients Who Did Not Have Adequate Glycaemic Control With Metformin.

Lead sponsor

Novartis Pharmaceuticals

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 19-35•HbA1c 6.5-9%

Primary endpoint

•Proportion of patients preferring each treatment regimen

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01518101

Org study IDCLMF237ADE03

Secondary ID2011-003818-16

Timeline

Milestones

Study first posted2012-01-25estimated

Last update posted2017-02-27actual

Study start2012-01 (month precision)

Primary completion2012-10actual (month precision)

Study completion2012-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Patients with type 2 diabetes

•Metformin monotherapy > 12 weeks

•Hemoglobin A1c (HbA1c) > 6.5 % and < 9.0 %

•Body mass Index (BMI) 19-35 (kg/m²)

Exclusion criteria

•acute diseases at randomization

•kidney diseases with creatinin > 120 µmol/l, glomerular filtration rate (GFR) <50 ml/min

•contraindication for Gliptins or glucagon-like-peptide-analogues according to the respective Summary of Product Characteristics (SmPC)

•previous use of dipeptidyl peptidase-4-inhibitors and GLP-1-mimetics

Other protocol-defined inclusion/exclusion criteria may apply.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Patient-reported / QoL

Glycemic / diabetes

Safety / tolerability / PK

Other (unclassified)

Glycemic / diabetes

2 endpoints

Secondary/protocol endpoint

Change from baseline in fasting plasma glucose at 12 weeks and 24 weeks

Time frame:From Baseline to 12 weeks and 24 weeks

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change From Baseline in Hemoglobin A1c (HbA1c) at week 12 and week 24

Time frame:From Baseline to 12 weeks and 24 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Patient-reported / QoL

3 endpoints

Primary/protocol endpoint

Proportion of patients preferring each treatment regimen

Time frame:At week 24

threshold achievement, descriptive

Secondary/protocol endpoint

Number of patients with treatment satisfaction for each treatment measured by Diabetes Treatment Satisfaction Questionnaire (TSQM-9)

Time frame:week 12, Week 24

descriptive, improvement

Secondary/protocol endpoint

Number of patients responding to subjective reasons of preference to each treatment

Time frame:Week 12, week 24

threshold achievement, descriptive

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Number of patients with adverse event, serious adverse events and death

Time frame:24 weeks

descriptive, event

componentsTreatment-emergent AEs (any), Serious AEs (any), Death (safety endpoint)

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Investigator preference and subjective reasons of preference to each treatment

Time frame:Week 12, week 24

categorical status, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study.
Therapeutic advances in endocrinology and metabolism2015 Aug (month)PMID26301063doi:10.1177/2042018815595584via CT.gov reference

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.